The estimated Net Worth of Renee P Tannenbaum is at least $1.36 Million dollars as of 16 May 2024. Renee Tannenbaum owns over 2,000 units of Zogenix Inc stock worth over $485,869 and over the last 13 years he sold ZGNX stock worth over $501,015. In addition, he makes $372,893 as Independent Director at Zogenix Inc.
Renee has made over 10 trades of the Zogenix Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of ZGNX stock worth $127,740 on 16 May 2024.
The largest trade he's ever made was exercising 55,375 units of Zogenix Inc stock on 6 March 2019 worth over $609,125. On average, Renee trades about 4,203 units every 159 days since 2012. As of 16 May 2024 he still owns at least 18,211 units of Zogenix Inc stock.
You can see the complete history of Renee Tannenbaum stock trades at the bottom of the page.
Dr. Renee P. Tannenbaum Ph.D. serves as Independent Director of the Company. She has served as a member of our board of directors since February 2015. Dr. Tannenbaum currently serves as Vice President of Global Alliances at Halozyme, Inc., where she is responsible for leading the team that executes the company’s alliances through partnerships and collaborations. Dr. Tannenbaum was previously Head of Global Customer Excellence at AbbVie from October 2012 to January 2016, where she was responsible for building commercial capabilities for the organization. Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm from April 2011 to October 2012 and Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., from May 2009 to January 2011, where she was responsible for revenue generation for Elan’s marketed products, preparing for the commercialization of the company’s pipeline, including its Alzheimer’s portfolio, and strengthening the company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, Dr. Tannenbaum spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions in operations and general management. Dr. Tannenbaum served as a director to Nordic Nanovector ASA, a publicly-traded company in Norway, and Cipher Pharmaceuticals, Inc. a Canadian publicly-traded company, from April to August 2016, Sharps Compliance Inc. from November 2012 to November 2014 and Immune Pharmaceuticals, Inc., a publicly-traded company, from August 2011 to October 2012. Dr. Tannenbaum retains a faculty position at the University of the Sciences’ Mayes College of Healthcare Business and Policy and serves as the Dean’s Professor.
As the Independent Director of Zogenix Inc, the total compensation of Renee Tannenbaum at Zogenix Inc is $372,893. There are 16 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of $10,346,800.
Renee Tannenbaum is 68, he's been the Independent Director of Zogenix Inc since 2017. There are 1 older and 21 younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.
Renee's mailing address filed with the SEC is 11055 FLINTKOTE AVENUE, C/O CARDIFF ONCOLOGY, INC., SAN DIEGO, CA, 92121.
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo und Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: